Human Longevity was founded in 2013 by J. Craig Venter, Peter Diamandis, and Robert Hariri. The company has not officially endorsed a plan to participate in an IPO. These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Human Longevity is a genomics-based health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype, and clinical data. The company's mission is "to extend healthy human life by revolutionizing human health and transforming the practice of medicine." The company has acquired Cypher Genomics and DoctorsForMe. Human Longevity, based in San Diego, has raised $330 million in venture capital funding from investors including Emerging Technology Partners, Threshold, StartUp Health, OS Fund, Illumina Ventures, GE Ventures, Celgene, and Amino Capital. The company has not disclosed recent valuation information, but in 2018 Human Longevity reported a significant drop in valuation, falling from $1.6 billion to $310 million.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/21/2024 | Series B-2 | $7.9MM | $xx.xx | $18.58B | Emerging Technology Partners, Panacea Venture, Shin Ryoku Trust, TVM Capital Healthcare | |
Price per Share
$xx.xx
Shares Outstanding
30,850,126
Liquidation Pref Order
1
Liquidation Pref As Multiplier
3.0x
Conversion Ratio
3.0x
Dividend Rate
9.5%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Emerging Technology Partners, Panacea Venture, Shin Ryoku Trust, TVM Capital Healthcare
|
||||||
08/21/2024 | Series B-1 | $32MM | $xx.xx | $18.58B | Emerging Technology Partners, Panacea Venture, Shin Ryoku Trust, TVM Capital Healthcare | |
Price per Share
$xx.xx
Shares Outstanding
102,860,812
Liquidation Pref Order
1
Liquidation Pref As Multiplier
3.0x
Conversion Ratio
3.0x
Dividend Rate
9.5%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Emerging Technology Partners, Panacea Venture, Shin Ryoku Trust, TVM Capital Healthcare
|
||||||
11/06/2019 | Series A-2 | $34.06MM | $xx.xx | $5.04B | Emerging Technology Partners | |
Price per Share
$xx.xx
Shares Outstanding
133,034,522
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Emerging Technology Partners
|
||||||
11/06/2019 | Series A-1 | $18MM | $xx.xx | $5.04B | Emerging Technology Partners | |
Price per Share
$xx.xx
Shares Outstanding
7,964,602
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.2x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Emerging Technology Partners
|